Corridor Business Journal:Coralville-based KemPharm announced this week that its prodrug treatment for attention deficit/hyperactivity disorder (ADHD) in patients between the ages of 6-12, called KP415, has met primary and secondary efficacy endpoints. The company said it would continue to gather clinical data for KP415 through 2018, including the completion of ongoing oral and intranasal Human Abuse Potential studies, and that it will likely be ready to submit a New Drug Application for KP415 with the FDA in the first quarter of 2019. KemPharm’s stock has soared 54.4 percent year-to-date compared with the industry’s increase of 3.2 percent, according to Zack’s Investment Research.